TrialBMC cancer2021

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.

Gabriel Tremblay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.